Clinical Trials Logo

Filter by:
NCT ID: NCT04406636 Active, not recruiting - Huntington Disease Clinical Trials

Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD

SHIELD HD
Start date: May 19, 2020
Phase:
Study type: Observational

SHIELD HD is an international, multisite, prospective, longitudinal cohort natural history study to assess the natural history of HD and its biomarkers that are associated with modulation of the number of cytosine-adenine-guanine (CAG) repeats in the mutant Huntingtin (HTT) gene. Approximately 60 patients will be enrolled into the study and followed for up to 24 months at clinical sites in North America and Europe. The results of this study will inform assessments for a future interventional treatment trial.

NCT ID: NCT04406441 Active, not recruiting - Pediatric Obesity Clinical Trials

Patient-Clinic-Community Integration to Prevent Obesity Among Rural Preschool Children

ENCIRCLE
Start date: August 17, 2020
Phase: N/A
Study type: Interventional

The goal of this research study is to compare two enhancements to well-child visits at Geisinger designed to promote family-centered counseling for the prevention of obesity in a high-risk population of rural, lower income, preschool-aged children. Compared to the standard well-child visit, enhancements will offer advantages to obesity prevention, parent involvement in counseling, lifestyle behaviors, and food resource management.

NCT ID: NCT04406272 Active, not recruiting - Glioblastoma Clinical Trials

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

NCT ID: NCT04405297 Active, not recruiting - Knee Osteoarthritis Clinical Trials

A Disease-based Treatment Study for Diagnosed Osteoarthritis Utilizing Adipose-derived Regenerative Cells

Start date: May 24, 2021
Phase:
Study type: Observational

This is a prospective, multi-location safety and effectiveness study, and data registry of autologous adult ADRCs generated by the Transpose® RT System in subjects with OA in the shoulder, wrist, knee, hip, or ankle.

NCT ID: NCT04404985 Active, not recruiting - Endo-vascular AVFs Clinical Trials

Endovascular vs Surgical Arteriovenous Fistula Outcomes

ESAVFO
Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Arteriovenous fistulas (AVFs) are the preferred type of vascular access for dialysis, but many of them fail to mature. There are two techniques of creating AVFs either the traditional way with surgery( Surgical AVFs) or novel per-cutaneous technique Endo- AVFs. Investigators will pilot an randomized clinical trial of endo-AVFs and surgical AVFs at University of Alabama at Birmingham to determine the feasibility of patient recruitment, randomization, and retention. This pilot study will set the stage for a full-scale randomized clinical trial in future.

NCT ID: NCT04404660 Active, not recruiting - Clinical trials for Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Start date: March 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

NCT ID: NCT04404595 Active, not recruiting - Pancreatic Cancer Clinical Trials

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Start date: October 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers

NCT ID: NCT04404283 Active, not recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

ECHELON-3
Start date: August 20, 2020
Phase: Phase 3
Study type: Interventional

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

NCT ID: NCT04404088 Active, not recruiting - Clinical trials for Grade 3a Follicular Lymphoma

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Start date: July 16, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib, lenalidomide, and rituximab may help to control the disease.

NCT ID: NCT04403022 Active, not recruiting - Colorectal Cancer Clinical Trials

da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures

Start date: June 3, 2021
Phase: N/A
Study type: Interventional

To confirm the safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in a complex colorectal procedure such as low anterior resections or right colectomy.